U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent LitigationGlobeNewsWire • 06/08/26
CorMedix: Bleak Short-Term Outlook, But Significantly Undervalued For The Long RunSeeking Alpha • 05/27/26
Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 05/14/26
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research • 05/07/26
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026GlobeNewsWire • 05/05/26
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation PatientsGlobeNewsWire • 04/27/26
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 03/05/26
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026GlobeNewsWire • 03/02/26